

LINCOLN
Cancer Incidence by Sex, 1993 - 1997
Expected and Observed Case Counts, with Standardized Incidence Ratios

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|---------------------------------------|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 4.51 | 5 | 111 | Male | 2.85 | 7 | 246 |
| Female | 1.44 | 4 | NC* | Female | 2.16 | 4 | NC* |
| Total | 5.95 | 9 | 151 | Total | 5.01 | 11 | 220 #+ |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 1.58 | 0 | NC* | Male | 0.85 | 1 | NC* |
| Female | 1.29 | 2 | NC* | Female | 0.70 | 0 | NC* |
| Total | 2.87 | 2 | NC* | Total | 1.55 | 1 | NC* |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 0.30 | 0 | NC* | Male | 3.77 | 2 | NC* |
| Female | 26.99 | 30 | 111 | Female | 2.89 | 0 | NC* |
| Total | 27.29 | 30 | 110 | Total | 6.66 | 2 | NC* |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 1.87 | 1 | NC* | Male | 3.15 | 1 | NC* |
| | | | | Female | 1.34 | 1 | NC* |
| | | | | Total | 4.49 | 2 | NC* |
| <u>Colon / Rectum</u> | | | | <u>Ovary</u> | | | |
| Male | 11.44 | 6 | 52 | Female | 3.32 | 1 | NC* |
| Female | 9.12 | 8 | 88 | | | | |
| Total | 20.56 | 14 | 68 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 1.70 | 3 | NC* | Male | 1.76 | 1 | NC* |
| Female | 0.47 | 0 | NC* | Female | 1.55 | 3 | NC* |
| Total | 2.17 | 3 | NC* | Total | 3.31 | 4 | NC* |
| <u>Hodgkin's Disease</u> | | | | <u>Prostate</u> | | | |
| Male | 0.79 | 0 | NC* | Male | 28.01 | 44 | 157 ~+ |
| Female | 0.61 | 0 | NC* | | | | |
| Total | 1.39 | 0 | NC* | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | <u>Stomach</u> | | | |
| Male | 2.75 | 0 | NC* | Male | 1.97 | 0 | NC* |
| Female | 1.49 | 0 | NC* | Female | 0.97 | 1 | NC* |
| Total | 4.24 | 0 | NC* | Total | 2.94 | 1 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.68 | 1 | NC* | Male | 1.13 | 1 | NC* |

| | | | | | | | |
|---|-------|----|-------|---|--------|-----|-----|
| Female | 0.45 | 0 | NC* | | | | |
| Total | 2.12 | 1 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 2.02 | 3 | NC* | Male | 0.60 | 1 | NC* |
| Female | 1.40 | 3 | NC* | Female | 1.54 | 2 | NC* |
| Total | 3.42 | 6 | 175 | Total | 2.13 | 3 | NC* |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | <u>Uteri, Corpus and Uterus, NOS</u> | | | |
| Male | 0.94 | 1 | NC* | | | | |
| Female | 0.33 | 0 | NC* | Female | 5.18 | 9 | 174 |
| Total | 1.27 | 1 | NC* | | | | |
| <u>Lung and Bronchus</u> | | | | <u>All Sites / Types</u> | | | |
| Male | 14.87 | 10 | 67 | Male | 93.07 | 88 | 95 |
| Female | 10.28 | 4 | NC* | Female | 80.94 | 80 | 99 |
| Total | 25.15 | 14 | 56 #- | Total | 174.02 | 168 | 97 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.05$ and $p \leq 0.01$ levels